Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 +0.62%69 5-Year Yield-on-Cost % is 4.60 as of Aug. 10, 2026, which is 217% above its 10-year median of 1.45. GuruFocus rates ROCO:4160 with a GF Score™ of 69/100 and a GF Value™ of NT$53.61 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 66.67% on this metric.
The historical rank and industry rank for Genetics Generation Advancement's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:4160'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.36 Med: 1.45 Max: 4.71
Current: 4.6
During the past 13 years, Genetics Generation Advancement's highest Yield on Cost was 4.71. The lowest was 0.36. And the median was 1.45.
ROCO:4160's 5-Year Yield-on-Cost % is ranked better than 66.67% of 63
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.43
vs ROCO:4160: 4.60
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Genetics Generation Advancement 5-Year Yield-on-Cost % Related Terms
ROCO:4160 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Genetics Generation Advancement (ROCO:4160) has a 5-Year Yield-on-Cost % of 4.60 as of Aug. 10, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Genetics Generation Advancement and its competitors. This is 217% above median its historical median of 1.45. Over the past decade, Genetics Generation Advancement's 5-Year Yield-on-Cost % has ranged from 0.36 to 4.71. According to the industry distribution chart, Genetics Generation Advancement ranks #21 out of 63 companies in the Medical Diagnostics & Research industry, placing it in the top 33.3%.
Is Genetics Generation Advancement's 5-Year Yield-on-Cost % too high?
Genetics Generation Advancement's current 5-Year Yield-on-Cost % of 4.60 is 217% above median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 4.71. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.43. Genetics Generation Advancement's value of 4.60 is 89.3% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #21 out of 63 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #21 out of 63 companies for 5-Year Yield-on-Cost %. This puts Genetics Generation Advancement in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Genetics Generation Advancement's value of 4.60 is 89.3% above this benchmark. Historically, Genetics Generation Advancement's own 5-Year Yield-on-Cost % has ranged from 0.36 to 4.71 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 2.43, Genetics Generation Advancement has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.43, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current 5-Year Yield-on-Cost % of 4.60 is 89.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current 5-Year Yield-on-Cost % is 4.60, which is 217% above median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.61, compared to a current price of NT$40.40 — trading 24.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.60, which is 217% above median its 10-year median of 1.45 and 89.3% above the Medical Diagnostics & Research industry median of 2.43. Genetics Generation Advancement's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current 5-Year Yield-on-Cost % is 4.60 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$40.40 is trading 24.6% below its estimated GF Value™ of NT$53.61.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
5-Year Yield-on-Cost %: 4.60 (217% above median its 10-year median of 1.45)
GF Value™: NT$53.61 vs. price of NT$40.40 (24.6% below fair value)
Industry Position: 89.3% above the Medical Diagnostics & Research median (#21 of 63)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
69GF Score
Get the complete analysis for ROCO:4160
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
